New kits for diagnosis of impaired cytokine, growth factors and HLA-G antigens
Public support
Provider
Ministry of Education, Youth and Sports
Programme
EUREKA - European co-operation in the sphere of applied and industrial research and development aimed at the support of multinational co-operation among industrial undertakings, research institutes and universities
Call for proposals
EUREKA 1 (SMSM200132005)
Main participants
EXBIO Praha, a.s.
Contest type
VS - Public tender
Contract ID
—
Alternative language
Project name in Czech
Diagnostické soupravy pro studium predikce biologických účinků interferonu a pro detekci sérových HLA-G antigenů
Annotation in Czech
Vývoj nových monoklonálních protilátek proti signálnímu proteinu STAT1 a proti jeho endogennímu inhibitoru SOC3 proteinu. Vývoj monoklonálních protilátek proti HLA-G a HLA-E antigenu. Konstrukce experimentálních ELISA souprav na sledování signálních prot, einů a sérových HLA-G antigenů. Ověření získaných protilátek a ELISA souprav na experimentálním a klinickém materiálu. Vypracování vyýrobních postupů výroby protilátek a ELISA souprav., ,
Scientific branches
R&D category
NV - Nonindustrial research (Applied research excluded Industrial research)
CEP classification - main branch
EI - Biotechnology and bionics
CEP - secondary branch
EC - Immunology
CEP - another secondary branch
FD - Oncology and haematology
OECD FORD - equivalent branches <br>(according to the <a href="http://www.vyzkum.cz/storage/att/E6EF7938F0E854BAE520AC119FB22E8D/Prevodnik_oboru_Frascati.pdf">converter</a>)
20801 - Environmental biotechnology<br>20802 - Bioremediation, diagnostic biotechnologies (DNA chips and biosensing devices) in environmental management<br>20803 - Environmental biotechnology related ethics<br>20901 - Industrial biotechnology<br>20902 - Bioprocessing technologies (industrial processes relying on biological agents to drive the process) biocatalysis, fermentation<br>20903 - Bioproducts (products that are manufactured using biological material as feedstock) biomaterials, bioplastics, biofuels, bioderived bulk and fine chemicals, bio-derived novel materials<br>30102 - Immunology<br>30204 - Oncology<br>30205 - Hematology<br>30401 - Health-related biotechnology<br>30402 - Technologies involving the manipulation of cells, tissues, organs or the whole organism (assisted reproduction)<br>30403 - Technologies involving identifying the functioning of DNA, proteins and enzymes and how they influence the onset of disease and maintenance of well-being (gene-based diagnostics and therapeutic interventions [pharmacogenomics, gene-based therapeutics])<br>30404 - Biomaterials (as related to medical implants, devices, sensors)<br>30405 - Medical biotechnology related ethics<br>40401 - Agricultural biotechnology and food biotechnology<br>40402 - GM technology (crops and livestock), livestock cloning, marker assisted selection, diagnostics (DNA chips and biosensing devices for the early/accurate detection of diseases) biomass feedstock production technologies, biopharming<br>40403 - Agricultural biotechnology related ethics
Completed project evaluation
Provider evaluation
U - Uspěl podle zadání (s publikovanými či patentovanými výsledky atd.)
Project results evaluation
9 new monoclonal antibodies against signal molecules of STAT 1 and SOCS, introduction in production programme
Solution timeline
Realization period - beginning
Jan 1, 2002
Realization period - end
Jan 1, 2004
Project status
U - Finished project
Latest support payment
—
Data delivery to CEP
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data delivery code
CEP/2005/MSM/MSM5OE/U/N/4:2
Data delivery date
Sep 18, 2007
Finance
Total approved costs
8,640 thou. CZK
Public financial support
4,048 thou. CZK
Other public sources
0 thou. CZK
Non public and foreign sources
4,592 thou. CZK